Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Advanced Solid Tumors

Contact:

NCT Number:

Protocol:

AAAR0263

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I/II

The purpose of the study is to test the safety of an investigational/study drug called BMS-986207 (also known as Anti TIGIT monoclonal antibody) administered alone, in combination with nivolumab, and in combination with nivolumab and ipilimumab. This study will investigate how research subjects/participants with advanced solid tumors tolerate these drugs and identify the highest dose or most suitable dose, of BMS-986207 alone, in combination with nivolumab, and in combination with nivolumab and ipilimumab in cancer research participants. This is the first study in which BMS-986207 will be administered to humans. Nivolumab and ipilimumab have been administered to and is approved for human use in multiple tumor types.

Are you Eligible? (Inclusion Criteria)

  • Patients must have advanced solid tumor
  • Patients must be in good physical shape. This means that patients must be able to walk, care for themselves, and do light physical activities such as light housework or office work.
  • This study is for patients age 18 or older
  • The participant must sign the consent for pretreatment and on treatment tumor biopsy samples

Specialty Area(s)

Colon and Rectal Cancer, Ovarian Cancer, Liver Cancer, Lung cancer, Immunotherapy

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032